Pharmaceutical - Markets & Marketing, Fycompa


Popular Filters

Eisai’s Fycompa debuts in France following reimbursement agreement


Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019


The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge


The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA


The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision


Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

Eisai joins trend to enter Russian pharma market, with Halaven launch


Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Eisai expands in South Africa, filing for approval of Halaven and Fycompa


Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst


Japanese drug major Eisai (TYO: 4523) has announced the first European launch today of Fycompa (perampanel),…

EisaiFycompaMarkets & MarketingNeurologicalPharmaceuticalResearchTropical diseasesVaccines

Zonegran Russian approval prompts Eisai's expansion in that market


Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran



Back to top